Approval · Notice of Compliance 6344 · 2005
REACTINE: Notice of Compliance 6344
Issued March 23, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6344
- Date
- March 23, 2005
- Company
- Pfizer Canada Inc., Consumer Healthcare DivisionMarkham, Ontario, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New claims: non-drowsy, lets you stay alert and perform normally, and can be used while driving
- Therapeutic class
- Histamine h1 receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE | Not yet assigned | — |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 5 MG per TAB
- CETIRIZINE HYDROCHLORIDE 10 MG per TAB
- CETIRIZINE HYDROCHLORIDE 5 MG per 5ML